Biocon Opens Its First Manufacturing Facility in the U.S. to Enhance Global Reach
In a significant milestone, Biocon Limited, a pioneering global biopharmaceutical firm, celebrated the inauguration of its very first U.S. manufacturing facility located in Cranbury, New Jersey. The event marked not just a new chapter in the company’s evolution but also highlighted its strategic commitment to enhancing patient access to essential therapies throughout the United States.
The ceremony, held on September 10, 2025, was graced by the presence of New Jersey's Governor, Phil Murphy, alongside Biocon’s Chairperson, Kiran Mazumdar-Shaw, and a myriad of esteemed guests encompassing dignitaries, customers, partners, and industry leaders. The facility, wholly owned by Biocon’s subsidiary, Biocon Generics Inc (BGI), adds to the company’s burgeoning global footprint in the biopharmaceutical landscape.
Biocon's journey to establishing this facility began with its acquisition of an Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023. The investment, exceeding $30 million, has culminated in a state-of-the-art manufacturing plant capable of producing up to 2 billion tablets annually. The facility is not only operational but is already delivering some products to the market, with many more slated for future release. This move is expected to significantly diversify Biocon’s manufacturing capabilities, bolster its supply chain, and enhance its connection with U.S. healthcare providers.
Kiran Mazumdar-Shaw expressed enthusiasm over this new venture, stating, 'This facility signifies a crucial moment in Biocon’s global expansion. It underscores our ongoing mission to support patients globally and highlights our determination to foster innovation within the healthcare sector. Governor Murphy’s attendance at this inauguration emphasizes the vital role Biocon plays in contributing to job creation and enhancing the healthcare landscape in the U.S.'
Biocon aims to fortify its partnerships and relationships with healthcare providers through this initiative. Siddharth Mittal, the CEO and Managing Director, echoed these sentiments, emphasizing the significance of establishing this presence in the U.S. 'Our strategic investment strategically positions us closer to our partners and the healthcare community in the U.S. This proximity will enable us to deliver high-quality, vertically integrated medicines more efficiently, ensuring supply chain resilience and expanding patient access globally.'
Governor Murphy also noted the importance of Biocon’s investment in New Jersey, affirming, 'Biocon’s commitment to opening its first U.S. manufacturing facility in our state marks a pivotal development not only for the company but also for New Jersey’s reputation as a crucial player in the global healthcare industry.'
Biocon Limited, a publicly listed company since 2004, has a robust portfolio focused on providing affordable access to complex therapies for chronic maladies, including diabetes, oncology, and autoimmune diseases. Their work spans the development of novel biologics, biosimilars, and complex small molecule APIs in key markets including India, the U.S., and Europe, with a commitment to innovation reflected in their pipeline of promising novel assets in immunotherapy.
Overall, the opening of the Cranbury facility symbolizes Biocon’s dedication to fostering innovation and strengthening the healthcare Ecosystem within the U.S. The company’s vision includes deeper engagement in healthcare sectors while aiming to enhance the standard of care for patients, ultimately working towards a healthier and more equitable future for all.
For more information about Biocon and its initiatives, please visit Biocon’s official website.
The ceremony, held on September 10, 2025, was graced by the presence of New Jersey's Governor, Phil Murphy, alongside Biocon’s Chairperson, Kiran Mazumdar-Shaw, and a myriad of esteemed guests encompassing dignitaries, customers, partners, and industry leaders. The facility, wholly owned by Biocon’s subsidiary, Biocon Generics Inc (BGI), adds to the company’s burgeoning global footprint in the biopharmaceutical landscape.
Biocon's journey to establishing this facility began with its acquisition of an Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023. The investment, exceeding $30 million, has culminated in a state-of-the-art manufacturing plant capable of producing up to 2 billion tablets annually. The facility is not only operational but is already delivering some products to the market, with many more slated for future release. This move is expected to significantly diversify Biocon’s manufacturing capabilities, bolster its supply chain, and enhance its connection with U.S. healthcare providers.
Kiran Mazumdar-Shaw expressed enthusiasm over this new venture, stating, 'This facility signifies a crucial moment in Biocon’s global expansion. It underscores our ongoing mission to support patients globally and highlights our determination to foster innovation within the healthcare sector. Governor Murphy’s attendance at this inauguration emphasizes the vital role Biocon plays in contributing to job creation and enhancing the healthcare landscape in the U.S.'
Biocon aims to fortify its partnerships and relationships with healthcare providers through this initiative. Siddharth Mittal, the CEO and Managing Director, echoed these sentiments, emphasizing the significance of establishing this presence in the U.S. 'Our strategic investment strategically positions us closer to our partners and the healthcare community in the U.S. This proximity will enable us to deliver high-quality, vertically integrated medicines more efficiently, ensuring supply chain resilience and expanding patient access globally.'
Governor Murphy also noted the importance of Biocon’s investment in New Jersey, affirming, 'Biocon’s commitment to opening its first U.S. manufacturing facility in our state marks a pivotal development not only for the company but also for New Jersey’s reputation as a crucial player in the global healthcare industry.'
Biocon Limited, a publicly listed company since 2004, has a robust portfolio focused on providing affordable access to complex therapies for chronic maladies, including diabetes, oncology, and autoimmune diseases. Their work spans the development of novel biologics, biosimilars, and complex small molecule APIs in key markets including India, the U.S., and Europe, with a commitment to innovation reflected in their pipeline of promising novel assets in immunotherapy.
Overall, the opening of the Cranbury facility symbolizes Biocon’s dedication to fostering innovation and strengthening the healthcare Ecosystem within the U.S. The company’s vision includes deeper engagement in healthcare sectors while aiming to enhance the standard of care for patients, ultimately working towards a healthier and more equitable future for all.
For more information about Biocon and its initiatives, please visit Biocon’s official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.